ArticleCancer research communications2025
SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
PARP inhibitors (PARPi) have reshaped the clinical management paradigm of multiple cancers, but none more than homologous recombination-deficient high-grade serous carcinoma (HGSC) of tubo-ovarian origin. In patients with HGSC that harbor BRCA1/2-mutations, PARPi maintenance therapy after first-line chemotherapy has resulted in significantly prolonged progression-free and overall survival. However, PARPi resistance is a major clinical challenge, and subsequent therapeutic options for patients with resistant disease remain limited. Whereas mechanisms of PARPi therapy have been described, there have been few clinical studies to translate these strategies into overcoming resistance. Elevated WNT signaling and T-cell factor (TCF) transcriptional activity contribute to PARPi resistance; however, directly targeting WNT signaling is challenging due to on-target adverse events. We tested an indirect WNT inhibitor, a dual CDC-like kinase and dual-specificity tyrosine phosphorylation-regulated kinase inhibitor, SM08502 (cirtuvivint), in combination with PARPi in multiple resistant HGSC models. We determined TCF transcriptional activity and differential gene expression with splicing analysis and used multispectral IHC to interrogate the tumor microenvironment. In PARPi-resistant models, SM08502 inhibits WNT/TCF transcriptional activity, reduces cell viability, and induces DNA damage. In addition, using multiple immune-compromised and immune-intact in vivo models of PARPi-resistant disease, SM08502, in combination with olaparib, significantly reduces disease progression, remodels the tumor immune microenvironment, and extends survival. Specifically, tumors treated with the SM08502/olaparib combination exhibit reduced immune-suppressive PD-1 and PD-L1 expression. This study provides strong preclinical evidence that SM08502, in combination with PARPi, may be an effective strategy to overcome PARPi resistance. SIGNIFICANCE: PARPi resistance is a major clinical challenge. Overcoming PARPi resistance will provide patients with therapeutic options. The study shows, in the context of resistant disease, the potential of targeting CDC-like kinase/dual-specificity tyrosine phosphorylation-regulated kinase alone and in combination with PARP inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.